Key Insights

Highlights

Treatment Research

5 treatments under study, led by Td Vaccine

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 2 (1)

Trial Status

Recruiting1
Terminated1

Clinical Trials (2)

Showing 2 of 2 trials
NCT06254326Phase 1RecruitingPrimary

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

NCT05297864Phase 2Terminated

PARP Inhibition for Gliomas (PI-4G or π4g)

Showing all 2 trials

Research Network

Common Treatments

  • Td Vaccine1
  • Ttrnadc Vaccines With Gmcsf1
  • Autologous Hematopoietic Stem Cells Hscs1
  • Ttrnaxalt1
  • Niraparib1

Active Sponsors

  • University of Florida1
  • GSK1
  • University of Oklahoma1
  • Oligo Nation, Inc1

Top Investigators

Related Conditions

  • Recurrent Glioma1
  • Recurrent Glioblastoma1
  • Recurrent Astrocytoma1
  • Progressive Oligodendroglioma1

Activity Timeline